BIAF Stock Jumps As Federal Deal Fuels Lung Test Growth

bioAffinity Technologies Inc. stocks have been trading up by 30.22 percent following highly positive coverage of its cancer diagnostics progress

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BIAF

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways BIAF Traders Need To Know

CyPath Lung test volume spiked 216% year over year in Q2 2026, with physician accounts up 122% and repeat orders up 71%, lifting first-half CyPath Lung revenue 159% to about $0.8M.
A new nationwide AvMEDICAL distribution deal opens federal channels for CyPath Lung, including VA and other government healthcare systems through established IDIQ contracting and a focused sales force.
Management is pushing BIAF’s CyPath Lung beyond early detection into post-treatment surveillance for lung cancer survivors, backed by a VA and military-supported longitudinal clinical trial.
Despite momentum, BIAF is still burning cash, held only about $2.4M on 2026/06/30 after a $3.2M equity raise, and faces Nasdaq delisting risk that points to ongoing dilution and execution pressure.
Q2 2026 EPS improved to -$0.64 from -$5.07 with revenue up to $1.5M from $1.27M as growing physician adoption and confidence in CyPath Lung drove commercial traction.

Live Update At 08:32:20 EDT: On Thursday, September 03, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 30.22%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF has turned into a classic high-growth, high-risk small-cap biotech chart. On the daily timeframe, BIAF went from sub-$1 closes in mid‑August 2026 to a close at $9.75 on 2026/09/02 after hitting an intraday high of $11.75. That is a massive multi-bagger move in a couple of weeks, the kind of range momentum traders hunt but also respect for its downside snap potential.

Under the hood, bioAffinity Technologies reported Q2 2026 revenue of $1.5M, up from $1.27M a year earlier, powered by rapid CyPath Lung adoption. EPS improved to -$0.64 from a brutal -$5.07, but BIAF is still firmly in loss territory. Key ratios show gross margin around 52.6%, yet profit margins are deeply negative and returns on equity and assets are sharply below zero, flagging a company still in heavy spending mode.

More Breaking News

The balance sheet matters here. BIAF finished 2026/06/30 with roughly $2.4M in cash and a current ratio of 1.4, supported by recent stock issuance. For traders, that mix — strong revenue growth, better EPS, but continuing cash burn and Nasdaq delisting risk — sets the stage for volatile, catalyst-driven trading.

Why Traders Are Watching BIAF’s Federal Deal And Momentum

BIAF has two big stories driving the tape right now: explosive growth in CyPath Lung and a new federal distribution channel. bioAffinity Technologies locked in a nationwide agreement with AvMEDICAL to distribute its CyPath Lung noninvasive lung cancer diagnostic into U.S. government healthcare systems, including the Department of Veterans Affairs. That matters because it plugs BIAF into existing IDIQ contracting frameworks and a government-focused sales force, instead of trying to build that reach alone.

For momentum traders, that kind of distribution deal can act like a lever. If AvMEDICAL executes, CyPath Lung volumes across VA and other federal systems can scale much faster than standard one‑doctor‑at‑a‑time outreach. The 216% year‑over‑year jump in test volume and 122% growth in physician accounts already show strong demand response. BIAF is not just signing deals; it is converting them into real usage.

BIAF is also widening the clinical footprint for CyPath Lung. The company is pushing beyond early detection into post-treatment surveillance for lung cancer survivors, positioning the test as an adjunct to imaging. With a VA and military-backed longitudinal trial underway, bioAffinity Technologies is clearly targeting long-term, recurring use per patient, not just one‑off testing.

On the intraday chart, BIAF’s recent premarket action shows a classic high-flyer pattern: wide 5‑minute candles, frequent $0.50–$1 swings, and a trading range between roughly $10 and $14 in the early session. That kind of range makes BIAF attractive to day traders who manage risk tightly and understand how quickly a hot biotech can reverse when news flow cools or dilution headlines hit.

Conclusion

BIAF sits at the intersection of strong product traction and serious balance-sheet pressure. CyPath Lung revenue grew 159% in the first half of 2026 to about $0.8M, and total Q2 revenue reached $1.5M, showing that bioAffinity Technologies is gaining real commercial ground. The AvMEDICAL deal and access to VA and other federal systems give BIAF a clear path to scale, while the shift into survivorship surveillance expands the long-term use case.

At the same time, BIAF remains a small company with limited cash, negative free cash flow, and Nasdaq delisting risk. The recent equity raise brought in $3.2M but also reminded traders that dilution is part of the story. Those forces, combined with a stock that just ran from under $1 to the high single digits and beyond, create a classic boom‑and‑pullback setup.

For active traders studying BIAF, the key is discipline. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” Watch how volume responds to updates on the AvMEDICAL rollout, VA and military trial data, and any delisting or capital-raise headlines. In the words often repeated by Tim Sykes, “The market doesn’t care about your opinion, only your discipline — cut losses quickly and let the best setups prove themselves.” Use that mindset when approaching volatile names like BIAF, and treat every trade as an educational and research exercise, not a guarantee of profit.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!